News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
HKEX, SFC Launch TECH; Specialist Technology/ Biotech Firms Allowed to Submit Listing Applications Confidentially
The Securities and Futures Commission (SFC) and HKEX (00388.HK), a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited, jointly announced today (6th) the launch of ...
Reset
Send
The window will close in 5 seconds
HKEX, SFC Launch TECH; Specialist Technology/ Biotech Firms Allowed to Submit Listing Applications Confidentially
Close
Recommend
13
Positive
24
Negative
6
 
 

The Securities and Futures Commission (SFC) and HKEX (00388.HK)  +3.800 (+1.038%)    Short selling $744.15M; Ratio 15.924%   , a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited, jointly announced today (6th) the launch of a dedicated Technology Enterprises Channel (TECH) to further facilitate New Listing applications from prospective Specialist Technology Companies and Biotech Companies, as well as a new confidential filing option for these companies.

In addition, the Exchange has updated the Guide for New Listing Applicants (the Guide) that these companies are presumed to have satisfied the Innovative Company Requirements and the external validation requirement for listing with a weighted voting right (WVR) structure under Main Board Chapter 8A.

Related NewsHSBC Research: Active Capital Mkt Remains Key Catalyst; BOC HONG KONG/ BANK OF E ASIA/ HKEX Preferred
TECH supports prospective Specialist Technology Companies and Biotech Companies in understanding applicable Listing Rules and preparing for their listing in Hong Kong before submitting formal New Listing applications through the following measures offered by the Exchange:

(1) Dedicating a specialized team with relevant experience in reviewing and providing guidance on Main Board Chapters 18C and 18A applications; (2) Engaging with prospective companies to gain deeper knowledge of their specific businesses and facilitate their comprehension of Listing Rule requirements; (3) Providing guidance on the eligibility and suitability for listing, such as the requirements for Core Products, the acceptance of other biotech products and/or clinical trials done under the regulation of different authorities, the qualifications and independence of Sophisticated Investors, acceptable sectors for Specialist Technology Industries, as well as factors for accepting new sectors/ industries outside the current scope; and (4) Providing opportunities to discuss and seek the Exchange’s preliminary guidance on case-specific issues arising under the Listing Rules.

Since Specialist Technology Companies and Biotech Companies are typically companies that are in their early stage of development or have yet to commercially launch their products, premature and prolonged disclosure of information on these companies’ operational strategies, proprietary technologies, and listing plans may pose heightened and disproportionate risks compared to other industries.

Related NewsCICC: HSI Could Return to 24,000 Lv. Under Optimistic Scenario; Tariff Talks, Domestic Stimulus Clarity Needed for Medium- to Long-Term
To assist these companies in mitigating these risks, the Exchange will permit these companies seeking a listing under Main Board Chapters 18C and 18A to submit their Application Proofs5 confidentially. For further details, please refer to Chapter 6.4 of the Guide. The confidential filing option shall be available for listing applications filed under Main Board Chapters 18C and 18A after today.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-07 16:25.)

AAStocks Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.